Adalimumab Anti‑drug Antibody for IBD

Use

Detectable serum adalimumab anti‑drug antibody may cause accelerated adalimumab clearance leading to reduced trough levels of adalimumab and a compromised clinical response. Patients with low trough adalimumab level and anti‑drug antibody are more likely to benefit from a switch in biologic therapy than from an increase in adalimumab dose. If adalimumab level is therapeutic and total adalimumab anti‑drug antibody is detected, adalimumab anti‑drug antibody may accelerate clearance of the drug, but the detected anti‑drug antibody may not be clinically significant. The anti‑drug antibody may not be functional or the level is inadequate to accelerate adalimumab clearance. For adalimumab responsive patients, anti‑drug antibody may disappear over time or increase, and, if increased, may cause sub‑therapeutic adalimumab levels and a loss of response in the future. Addition of immuno‑suppressive agents to the treatment regimen may suppress development of anti‑drug antibody. Quest Diagnostics adalimumab anti‑drug antibody levels are determined with an assay that measures both free and bound anti‑drug antibody. Therefore, serum rheumatoid factor will not cause false negative adalimumab anti‑drug antibody results.